Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CARDIOVASCULAR DISEASE

Lessons from SGLT-2 inhibitors: rethinking endpoints for heart failure studies

Nature Medicine volume 27, pages 1872–1873 (2021)Cite this article

Subjects

SGLT-2 inhibitors show promise for treatment of heart failure with preserved ejection fraction, but clinical data are nuanced. Appropriate endpoint selection will be key to deciphering their benefits.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Potential endpoints in clinical trials for heart failure with preserved ejection fraction.

References

  1. McMurray, J. J. V. et al. New Engl. J. Med. 381, 1995–2008 (2019).

    Article  CAS  Google Scholar 

  2. Packer, M. et al. N. Engl. J. Med. 383, 1413–1424 (2020).

    Article  CAS  Google Scholar 

  3. Anker, S. D. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2107038 (2021).

  4. Nassif, M. E. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01536-x (2021).

  5. Spertus, J. et al. Am. Heart J. 150, 707–715 (2005).

    Article  Google Scholar 

  6. Butler, J. et al. Eur. J. Heart Fail. 22, 999–1005 (2020).

    Article  Google Scholar 

  7. Pedro, F. J. et al. J. Am. Coll. Cardiol. 68, 2690–2707 (2016).

    Article  Google Scholar 

  8. Anker, S. D. et al. Eur. J. Heart Fail. 21, 1279–1287 (2019).

    Article  CAS  Google Scholar 

  9. Abraham, W. T. et al. Eur. Heart J. 42, 700–710 (2021).

    Article  CAS  Google Scholar 

  10. Treatment for Heart Failure: Endpoints for Drug Development – Guidance for Industry (US FDA, HHS, 2019).

  11. Reddy, Y. N. V. et al. Eur. J. Heart Fail. 22, 1009–1018 (2020).

    Article  CAS  Google Scholar 

  12. Greene, S. J. et al. Circulation 138, 1039–1053 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA

    Sheng Fu, Sheldon E. Litwin & Ryan J. Tedford

  2. Division of Cardiology, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA

    Sheldon E. Litwin

Authors
  1. Sheng Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheldon E. Litwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryan J. Tedford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryan J. Tedford.

Ethics declarations

Competing interests

S.E.L. is on the events adjudication committee for CVRx. S.E.L. provides consultation and is on the patient selection committee for Axon Therapeutics. R.J.T. reports general disclosures to include consulting relationships with Medtronic, Abbott, Aria CV Inc., Acceleron, Itamar, Edwards LifeSciences, Eidos Therapeutics, Lexicon Pharmaceuticals, Gradient, CareDx and United Therapeutics. R.J.T. is on a steering committee for Acceleron and Abbott, as well as a research advisory board for Abiomed. R.J.T. also does hemodynamic core lab work for Actelion and Merck. S.F. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fu, S., Litwin, S.E. & Tedford, R.J. Lessons from SGLT-2 inhibitors: rethinking endpoints for heart failure studies. Nat Med 27, 1872–1873 (2021). https://doi.org/10.1038/s41591-021-01565-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01565-6

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing